<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444560</url>
  </required_header>
  <id_info>
    <org_study_id>microRNA4</org_study_id>
    <nct_id>NCT01444560</nct_id>
  </id_info>
  <brief_title>miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi</brief_title>
  <official_title>The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length,
      capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs
      (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of
      complementarity. miRNAs have recently been shown to play pivotal roles in diverse
      developmental and cellular processes and linked to a variety of skin diseases and cancers. In
      the present study, the investigators examines the expression profiles of miRNA machinery
      components such as miRNA maturation and transport factors, microprocessor complex and RISC
      subunits in cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi
      were included in the study. Punch biopsies were harvested from the center of the tumors. The
      miRNA machinery components were detected by quantitative real-time reverse transcriptase
      polymerase chain reaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <condition>Nevi</condition>
  <arm_group>
    <arm_group_label>Cutaneous Melanoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous Melanoma Metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Melanocytic Nevi</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      human skin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cutaneous melanoma, cutaneous melanoma metastases, benign melanocytic nevi
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cutaneous melanoma

          -  cutaneous melanoma metastases

          -  benign melanocytic nevi

        Exclusion Criteria:

          -  other forms of malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Falk G Bechara, PD Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum</name>
      <address>
        <city>Bochum</city>
        <state>NRW</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, Bechara FG. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012 Oct;350(1):119-26. doi: 10.1007/s00441-012-1446-0. Epub 2012 Jun 17.</citation>
    <PMID>22706980</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruhr University of Bochum</investigator_affiliation>
    <investigator_full_name>Michael Sand</investigator_full_name>
    <investigator_title>Postdoc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

